CTT PHARMACEUTICAL HOLDINGS, INC.

CTT Pharmaceutical Holdings, Inc. announced it received a continuation-in-part (CIP) patent approval from the U.S. Patent Office for its micelle delivery technology. The patent, effective August 11, 2026, specifically covers nicotine, vitamins, and caffeine. This approval allows the company's technology to be utilized in various dissolvable forms, including strips, gum, pouches, lozenges, and dissolving tablets, enhancing its intellectual property portfolio.

CTT Pharmaceutical Holdings, Inc. has registered up to 6,250,000 shares of common stock for sale by RH2 Partners under an Equity Line of Credit (ELOC) agreement. While the company will not receive proceeds from the selling stockholder's sales, it may receive up to $10,000,000 from sales to the selling stockholder under the ELOC, which will be used for working capital and manufacturing equipment. The company, a development-stage entity with a history of losses and a 'going concern' qualification, acknowledges significant dilution risk, especially given its recent stock price of $0.08 per share.

CTT PHARMACEUTICAL Holdings, Inc. has filed an S-1 registration statement for the resale of up to 6,250,000 shares of common stock by a selling stockholder, RH2 Partners, under an Equity Line of Credit (ELOC) agreement. While the company will not receive proceeds from the resale, it may receive up to $10,000,000 from selling shares to the selling stockholder under the ELOC for working capital and equipment. The company, a development-stage firm with a history of losses and a "going concern" qualification, aims to limit dilution, especially at current stock price levels, and plans to raise no more than $1 million under the ELOC unless its stock price exceeds $1.

CTT Pharmaceutical Holdings, Inc. has filed an S-1 form detailing an Equity Line of Credit (ELOC) agreement with RH2, allowing the company to potentially sell up to 6,250,000 shares of common stock for up to $10 million. While the company will not receive proceeds from the initial sale by the Selling Stockholder, it may receive funds from subsequent sales under the ELOC, intended for working capital and operational improvements. The company expresses concern about potential dilution at current stock prices and plans to limit ELOC usage until the stock price increases.

CTT Pharmaceutical Holdings filed an S-1 registration statement for the resale of up to 6,250,000 shares of common stock by RH2 Partners, a selling stockholder. While the company will not receive proceeds from this resale, it may receive up to $10,000,000 from the sale of shares to RH2 Partners under an Equity Line of Credit (ELOC) agreement. The company, a development-stage entity specializing in fast-dissolving drug delivery systems, plans to use any ELOC proceeds for working capital, strategic, and general corporate purposes, prioritizing at least $500,000 for in-house manufacturing equipment. CTT Pharma reported losses of $250,229 in 2024 and $155,907 in 2025, and its auditors have issued a "going concern" qualification, highlighting the need for this financing despite potential dilution.